Arcutis Biotherapeutics I... (ARQT)
| Bid | 12.76 |
| Market Cap | 1.53B |
| Revenue (ttm) | 196.54M |
| Net Income (ttm) | -140.04M |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -11.08 |
| Forward PE | -15.55 |
| Analyst | Buy |
| Ask | 12.94 |
| Volume | 874,254 |
| Avg. Volume (20D) | 2,510,286 |
| Open | 13.13 |
| Previous Close | 12.59 |
| Day's Range | 12.66 - 13.21 |
| 52-Week Range | 6.99 - 17.75 |
| Beta | 1.68 |
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp ...
Analyst Forecast
According to 6 analyst ratings, the average rating for ARQT stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 51.69% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call TranscriptArcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance & Investor Relations Frank Wata...
